NovaCardia & Domain: New-Model Spec Pharma Investing

01 Sep 2007

• By Roger Longman

Domain partner Eckard Weber has become a master of the one-two punch in venture investing. The process (now in its third iteration following Merck's $350 million acquisition of NovaCardia): find a drug no one cares about; create a low-infrastructure company around it; find a second drug; sell off the lead drug through an acquisition; develop the second drug a bit more with the same management; then sell that one too. The first deal at a minimum pays back the investors; the second deal juices the returns. It's a model many VCs want to follow.

Investing in specialty pharma depends more on capital efficiency than spectacular scientific or clinical success. And the new master of this theme is Domain Associates, whose returns--says one of its limiteds--are now among the best in the industry (which, he notes, hasn’t always been true).

Domain’s latest essay in capital efficiency: NovaCardia Inc. Set up in 2001, the company raised $88 million, and it used roughly $50 million before Merck & Co. Inc. acquired it...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Regeneron Buys Tirzepatide-Like Product With Eye On Muscle-Preserving Combinations

02 Jun 2025

• By Jessica Merrill

Regeneron is bringing in its own GIP/GLP-1 agonist, establishing a path to develop proprietary obesity drug combinations with its internal muscle-sparing drugs.